In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage’s TRAP cage platform, a novel drug delivery system utilizing virus-like particles (VLPs) to significantly enhance the efficacy and safety of current ADCs. By focusing on improving the antibody-to-drug ratio (DAR) of ADCs, the TRAP cage platform aims to create treatments that are not only more effective but also come with fewer side effects, addressing a critical need in modern oncology.
Krzysztof Brzózka, Ryvu’s Chief Scientific Officer, emphasized the strategic importance of this collaboration, noting that combining Ryvu’s small molecule expertise and innovative ADC payloads with nCage’s advanced platform could pave the way for groundbreaking therapies. John Bason, CEO of nCage, echoed these sentiments, highlighting the potential for developing sophisticated products targeting viral elements and expanding the company’s reach. The two companies have committed to joint ownership of all generated data and will share costs, underscoring their commitment to cooperative innovation.
Collaboration Details
Ryvu Therapeutics and nCage Therapeutics are forging ahead in the realm of cancer treatment through a new research collaboration focused on creating a next-generation antibody-drug conjugate (ADC) platform. Their partnership leverages nCage’s TRAP cage platform, a unique drug delivery system employing virus-like particles (VLPs) to boost the effectiveness and safety of current ADCs. The primary goal is to enhance the antibody-to-drug ratio (DAR) of ADCs, leading to treatments that are more potent and less toxic, meeting a crucial need in contemporary oncology.
Krzysztof Brzózka, Ryvu’s Chief Scientific Officer, highlighted the strategic value of this collaboration. By merging Ryvu’s small molecule prowess and innovative ADC payloads with nCage’s cutting-edge platform, they aim to pioneer groundbreaking cancer therapies. John Bason, CEO of nCage, also expressed optimism, underlining the potential to develop sophisticated products targeting viral components and broadening the company’s scope. The two companies will jointly own all data generated from this endeavor and share costs, demonstrating their dedication to cooperative innovation and joint advancement.
